Dana Walsh, Ph.D.
Senior Microbiome Scientist at CosmosID
Research Expertise
About
Publications
Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)
Scientific Reports / Dec 16, 2019
Walsh, D. M., Hokenstad, A. N., Chen, J., Sung, J., Jenkins, G. D., Chia, N., Nelson, H., Mariani, A., & Walther-Antonio, M. R. S. (2019). Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome). Scientific Reports, 9(1). https://doi.org/10.1038/s41598-019-55720-8
Distinguishing Human Peripheral Blood NK Cells from CD56dimCD16dimCD69+CD103+ Resident Nasal Mucosal Lavage Fluid Cells
Scientific Reports / Feb 21, 2018
Rebuli, M. E., Pawlak, E. A., Walsh, D., Martin, E. M., & Jaspers, I. (2018). Distinguishing Human Peripheral Blood NK Cells from CD56dimCD16dimCD69+CD103+ Resident Nasal Mucosal Lavage Fluid Cells. Scientific Reports, 8(1). https://doi.org/10.1038/s41598-018-21443-5
Alterations in airway microbiota in patients with PaO2/FiO2 ratio ≤ 300 after burn and inhalation injury
PLOS ONE / Mar 30, 2017
Walsh, D. M., McCullough, S. D., Yourstone, S., Jones, S. W., Cairns, B. A., Jones, C. D., Jaspers, I., & Diaz-Sanchez, D. (2017). Alterations in airway microbiota in patients with PaO2/FiO2 ratio ≤ 300 after burn and inhalation injury. PLOS ONE, 12(3), e0173848. https://doi.org/10.1371/journal.pone.0173848
Bridging preclinical and clinical gut microbiota research using the ex vivo SIFR® technology
Frontiers in Microbiology / Apr 14, 2023
Van den Abbeele, P., Deyaert, S., Thabuis, C., Perreau, C., Bajic, D., Wintergerst, E., Joossens, M., Firrman, J., Walsh, D., & Baudot, A. (2023). Bridging preclinical and clinical gut microbiota research using the ex vivo SIFR® technology. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1131662
Development and Validation of a Novel Microbiome-Based Biomarker of Post-antibiotic Dysbiosis and Subsequent Restoration
Frontiers in Microbiology / Jan 04, 2022
Blount, K., Jones, C., Walsh, D., Gonzalez, C., & Shannon, W. D. (2022). Development and Validation of a Novel Microbiome-Based Biomarker of Post-antibiotic Dysbiosis and Subsequent Restoration. Frontiers in Microbiology, 12. https://doi.org/10.3389/fmicb.2021.781275
Porphyromonas somerae Invasion of Endometrial Cancer Cells
Frontiers in Microbiology / Jul 23, 2021
Crooks, T. A., Madison, J. D., Walsh, D. M., Herbert, W. G., Jeraldo, P. R., Chia, N., Cliby, W. A., Kaufmann, S. H., & Walther-Antonio, M. R. S. (2021). Porphyromonas somerae Invasion of Endometrial Cancer Cells. Frontiers in Microbiology, 12. https://doi.org/10.3389/fmicb.2021.674835
1064. Treatment Success in Reducing Recurrent Clostridioides difficile Infection with Investigational Live Biotherapeutic RBX2660 Is Associated with Microbiota Restoration: Consistent Evidence from a Phase 3 Clinical Trial
Open Forum Infectious Diseases / Nov 01, 2021
Blount, K., Walsh, D. M., Gonzalez, C., & Shannon, B. (2021). 1064. Treatment Success in Reducing Recurrent Clostridioides difficile Infection with Investigational Live Biotherapeutic RBX2660 Is Associated with Microbiota Restoration: Consistent Evidence from a Phase 3 Clinical Trial. Open Forum Infectious Diseases, 8(Supplement_1), S624–S625. https://doi.org/10.1093/ofid/ofab466.1258
129. Antimicrobial Resistance Genes Were Reduced Following Administration of Investigational Microbiota-Based Live Biotherapeutic RBX2660 to Individuals with Recurrent Clostridioides difficile Infection
Open Forum Infectious Diseases / Nov 01, 2021
Hau, H., Walsh, D. M., Gonzalez, C., Shannon, B., & Blount, K. (2021). 129. Antimicrobial Resistance Genes Were Reduced Following Administration of Investigational Microbiota-Based Live Biotherapeutic RBX2660 to Individuals with Recurrent Clostridioides difficile Infection. Open Forum Infectious Diseases, 8(Supplement_1), S79–S79. https://doi.org/10.1093/ofid/ofab466.129
Abstract A70: Metformin alters the gut microbiota of ovarian cancer patients treated with carboplatin/paclitaxel chemotherapy and enhances sensitivity in resistant tumors
Clinical Cancer Research / Aug 01, 2018
Walsh, D. M., Mert, I., Jun, C., Hou, X., Weroha, S. J., & Walther-Antonio, M. (2018). Abstract A70: Metformin alters the gut microbiota of ovarian cancer patients treated with carboplatin/paclitaxel chemotherapy and enhances sensitivity in resistant tumors. Clinical Cancer Research, 24(15_Supplement), A70–A70. https://doi.org/10.1158/1557-3265.ovca17-a70
LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections
Open Forum Infectious Diseases / Oct 01, 2019
Orenstein, R., Mische, S., Mische, S., Blount, K., Blount, K., Bancke, L., Su, X., Walsh, D., Harvey, A., Gonzalez, C., Gerding, D. N., & Gerding, D. N. (2019). LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections. Open Forum Infectious Diseases, 6(Supplement_2), S994–S995. https://doi.org/10.1093/ofid/ofz415.2488
30. Antimicrobial Resistance Genes Are Reduced Following Administration of Investigational Microbiota-based Therapeutic RBX7455 to Individuals with Recurrent clostrioides Difficile Infection
Open Forum Infectious Diseases / Oct 01, 2020
Walsh, D., Gonzalez, C., Shannon, B., & Blount, K. (2020). 30. Antimicrobial Resistance Genes Are Reduced Following Administration of Investigational Microbiota-based Therapeutic RBX7455 to Individuals with Recurrent clostrioides Difficile Infection. Open Forum Infectious Diseases, 7(Supplement_1), S16–S16. https://doi.org/10.1093/ofid/ofaa417.029
29. Rapid Restoration of Bile Acid Compositions After Treatment with Investigational Microbiota-based Therapeutic RBX2660 for Recurrent clostrioides Difficile Infection
Open Forum Infectious Diseases / Oct 01, 2020
Ferdyan, N., Papazyan, R., Walsh, D., Klein, S., Qi, S., Blount, K., Srinivasan, K., & Fuchs, B. (2020). 29. Rapid Restoration of Bile Acid Compositions After Treatment with Investigational Microbiota-based Therapeutic RBX2660 for Recurrent clostrioides Difficile Infection. Open Forum Infectious Diseases, 7(Supplement_1), S15–S16. https://doi.org/10.1093/ofid/ofaa417.028
Mo1931 FAILURE IS NOT FINAL: CLINICAL RESPONSE AND MICROBIOME RESTORATION BY INVESTIGATIONAL DRUG RBX2660 ARE NOT COMPROMISED FOLLOWING PREVIOUS NON-RESPONSE FOR PREVENTING CLOSTRIDIOIDES DIFFICILE RECURRENCE
Gastroenterology / May 01, 2020
Steiner, T. S., Walsh, D. M., Gonzalez, C., Shannon, B., Su, X., & Blount, K. (2020). Mo1931 FAILURE IS NOT FINAL: CLINICAL RESPONSE AND MICROBIOME RESTORATION BY INVESTIGATIONAL DRUG RBX2660 ARE NOT COMPROMISED FOLLOWING PREVIOUS NON-RESPONSE FOR PREVENTING CLOSTRIDIOIDES DIFFICILE RECURRENCE. Gastroenterology, 158(6), S-982. https://doi.org/10.1016/s0016-5085(20)33128-0
Abstract PR09: Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome): Putative role of Porphyromonas somerae in the disease
Cancer Research / Apr 15, 2020
Walther-Antonio, M., Walsh, D., Hokenstad, A., Chen, J., Sung, J., Jenkins, G., Chia, N., Nelson, H., & Mariani, A. (2020). Abstract PR09: Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome): Putative role of Porphyromonas somerae in the disease. Cancer Research, 80(8_Supplement), PR09–PR09. https://doi.org/10.1158/1538-7445.mvc2020-pr09
3296 Endometrial cancer microbiome biomarker for disease detection and microbial role in the disease
Journal of Clinical and Translational Science / Mar 01, 2019
Walther-Antonio, M., Walsh, D., Liu, Y., Yao, J., Chia, N., Nelson, H., & Mariani, A. (2019). 3296 Endometrial cancer microbiome biomarker for disease detection and microbial role in the disease. Journal of Clinical and Translational Science, 3(s1), 104–104. https://doi.org/10.1017/cts.2019.238
The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial
Gut Microbes / Oct 21, 2022
Garvey, S. M., Mah, E., Blonquist, T. M., Kaden, V. N., & Spears, J. L. (2022). The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial. Gut Microbes, 14(1). https://doi.org/10.1080/19490976.2022.2122668
Education
University of North Carolina at Chapel Hill
Ph.D., Toxicology / May, 2016
Concordia College - Minnesota
B.A., Biology / December, 2009
Experience
CosmosID
Senior Microbiome Scientist / June, 2023 — Present
• Consult with clients to advise the best approach for their microbiome and metabolomics study design, sample collection and storage, sequencing and metabolomics methods, and bioinformatics and statistical analysis • Create custom analyses and reports helping clients understand their data • Manage and review scientific newsletters and blogs • Develop and test new methods for innovative data analysis • Promoted to senior microbiome scientist to lead custom project analysis and integration of new analysis methods and pipelines • Managed the bioinformatics team in sequencing production and project delivery
Microbiome Scientist / August, 2021 — June, 2023
• Identified the impact of microbiome-based therapeutics on subjects with Clostridioides difficile infection through analysis of micrbial community, functional, and metabolomics data • Established new methodologies for integration of complex microbial compositional, functional, and metabolomics data in the programming language R • Managed and developed relationships with microbiome analysis collaborators to drive high-quality and novel analysis methods and product development • Presented at least one oral talk per year at a national conference on the impact of biotherapeutics on the microbiome
NirvanaBiome
Microbiome Consultant / January, 2023 — Present
• Meet with customers (individuals and clinicians) to explain their gut microbiome test results • Provide a basic understanding of the gut microbiome and its importance in health along with individualized interpretation of results and recommendations of over-the-counter interventions that may help (such as the use of specific pre- and probiotics or dietary recommendations)
Rebiotix
Microbiome Analysis Scientist / June, 2019 — August, 2021
• Identified the impact of microbiome-based therapeutics on subjects with Clostridioides difficile infection through analysis of micrbial community, functional, and metabolomics data • Established new methodologies for integration of complex microbial compositional, functional, and metabolomics data in the programming language R • Managed and developed relationships with microbiome analysis collaborators to drive high-quality and novel analysis methods and product development • Presented at least one oral talk per year at a national conference on the impact of biotherapeutics on the microbiome
Mayo Clinic
Postdoctoral Research Fellow / October, 2016 — June, 2019
• Investigated the role of the vaginal and uterine microbiota in development and treatment of ovarian and endometrial cancer using human, mouse, and cell models • Determined the role of metformin in altering the gut microbiota during chemotherapy treatment for ovarian cancer in a patient-derived xenograft mouse model • Analyzed reproductive tract microbiota from patients with endometrial cancer to identify early vaginal biomarkers of disease using R • Developed an invasion assay to determine pathogenicity of specific members of the microbiota in endometrial and ovarian cancer. • Carried out complementary in vitro tissue culture work to determine the role of specific microbial products (bile acids and short-chain fatty acids) in killing of tumor cells.
Join Dana on NotedSource!
Join Now
At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.
For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.
For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.
Expert Institutions
Proudly trusted by
